Bringing the fundamentals into focus…
Back to Inovio Pharmaceuticals, Inc.
How Inovio Pharmaceuticals, Inc. stacks up
INO · against 165 other Healthcare companies of similar size
Growth
0/ 100
Near the bottom of its peers.
Ranked #164 of 166 · scores higher than 0% of peers
Bars: peers in each 10-point band of the growth score25 peers with a growth score of 0–9, including INO · Click a bar to see the companies
Why growth scores 0?
Weighted metrics compared with all Healthcare companies.Mainly because of its 3-year revenue growth and revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over three years: weaker than 100% of peers. 3-year revenue growth: -81.5% vs peer median 5.8%
- slower revenue growth over the last year: weaker than 97% of peers. Revenue growth: -70.0% vs peer median 6.1%
- Earnings per share growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = INO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | INO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 177 reported | -70.0% | 3.9% | 6% | 33% | |
| Earnings per share growthHigher is better · 65 reported | Not reported | 0.9% | — | — | 33% |
| 3-year revenue growthHigher is better · 163 reported | -81.5% | 3.9% | 1% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around INO| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 1 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 1 | 90M USD | 99 | 27 | |
| 1 | 97M USD | 99 | 63 | |
| 158 | 271M USD | 3 | 14 | |
| 158 | 215M USD | 3 | 34 | |
| 163 | 327M USD | 1 | 11 | |
| 164 | 454M AUD (≈$299M) | 0 | 7 | |
| 164 | 172M USD | 0 | 3 | |
| 164 | 149M USD | 0 | 10 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score